In LDOC1(+) EGFRM NSCLC tumors, LDOC1 may compete with EGFR for AP-1 and AP-2 binding, preventing CMI of EGFR–EGFR complexes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.